BioCryst Pharma rises after bigger quarterly sales
ReutersAug 4, 2025 11:44 AM
** Shares of drugmaker BioCryst Pharmaceuticals BCRX.O rise 6.3% to $8.45 premarket
** BCRX posts Q2 revenue of $163.4 million, compared with $109.3 million a year ago
** Company maintains its 2025 revenue forecast for its skin disease drug, Orladeyo, to be between $580 million and $600 million
** Sales of Orladeyo for the quarter rose 45% to $156.8 million
** BioCryst plans to retire all remaining term debt after its European business sale closes in early October
** Up to last close, stock up 5.7% YTD
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
AMD Q2 FY2025 Earnings Review: Impressive Growth Stumbles on Export Control Hurdles
TradingKey - Advanced Micro Devices, Inc. (NASDAQ: AMD) released its Q2 FY2025 earnings on August 5, 2025, after market close, delivering robust results driven by record sales in its Data Center and Client segments. Despite a 32% YoY revenue increase, surpassing expectations, the stock dipped aroundTradingKey
31 minutes ago
Post-NFP Shocker: What It Means for Your Portfolio
TradingKey - The latest data from the U.S. Bureau of Labor Statistics delivered a wake-up call. Job gains from the prior two months were revised down by 258,000 — a surprisingly large downgrade.TradingKey
19 hours ago
China July Inflation Preview: Low Inflation Risks May Ease
TradingKey - On 9 August 2025, China's National Bureau of Statistics will release July inflation data as scheduled. The market widely expects the Consumer Price Index (CPI) for July to shift from June’s 0.1% year-on-year increase to negative growth.TradingKey
19 hours ago
